Oncology development strategy

We examine a plan the way a development committee, a skeptical investor or a regulator eventually will, and rebuild the weaker parts with your team.

• Clinical positioningThe disease setting and line of therapy, the current standard of care and its limits, and the benefit a new agent would have to show to change practice.
• Population and indication selectionTrade-offs among tumor types, biomarker-defined groups and lines of therapy, including how to expand without diluting the signal.
• Evidence architectureStudy sequence, comparator choices, endpoints, dose-optimization strategy, and the point at which a randomized comparison becomes necessary.
• Dose, benefit–risk and regulatory preparationHow the dose will be selected, how benefit and risk will be judged for the intended patients, and which regulatory questions need an answer before the next commitment.
• Milestones and decision criteriaWhat each study has to show, and which results would lead you to continue, change course or stop.
• Risks and dependenciesThe clinical, operational and regulatory dependencies that could change the plan.

Most oncology programs that stall do so because an early study did not generate the evidence the next decision needed: an expansion cohort too heterogeneous to interpret, a dose chosen on tolerability alone, a single-arm result in a setting that now expects a randomized comparison.

A plan that names the decision each study must support avoids much of this. Strategy is also the basis for financing and partnering narratives, so weaknesses surface there if they are not found earlier.

• Choosing a lead indicationfrom several plausible options.
• Moving from early signals to a randomized program,and deciding what has to be shown first.
• Preparing a financing or board go/no-gothat needs an independent clinical view.
• Revisiting the planafter a competitor readout, a regulatory change or disappointing data.

1. Define the decision What must be decided, by whom and by when, and what is already fixed.
2. Assess the evidence you have Clinical, nonclinical and translational data, and what they support for each candidate path.
3. Build and test the options Usually two or three credible paths, compared on the likelihood of a decisive result, time, cost drivers and regulatory fit.
4. Recommend and document A preferred path with explicit assumptions and decision criteria, discussed with your leadership team.

• A clinical strategy memorandum with the recommended path and the alternatives considered
• An evidence-gap and development-risk register
• A milestone roadmap with decision criteria and dependencies
• A working session with your leadership or board

• StructureA focused independent review of an existing plan, a development-plan project, or scheduled strategic support that can extend into fractional leadership.
• What we need from youThe target product profile, available clinical and nonclinical summaries, the current plan, and the decision you have to make.
• Roles and limitsStatistical design, clinical pharmacology, CMC and nonclinical questions are brought to the relevant specialists when needed. Recommendations are only as strong as the evidence available.